Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Ciforadenant |
Trade Name | |
Synonyms | CPI-444|CPI 444|CPI444|V81444||V-81444 |
Drug Descriptions |
Ciforadenant (CPI-444) is an antagonist of the adenosine receptor A2aR, which may relieve adenosine-mediated immune suppression and enhance antitumor activity (PMID: 29923026, PMID: 30131376). |
DrugClasses | Adenosine Targeting 23 |
CAS Registry Number | 1202402-40-1 |
NCIT ID | C125659 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Atezolizumab + Ciforadenant | Atezolizumab Ciforadenant | 0 | 2 |
Ciforadenant | Ciforadenant | 0 | 2 |
Ciforadenant + CPI-006 | CPI-006 Ciforadenant | 0 | 1 |
Ciforadenant + Daratumumab | Ciforadenant Daratumumab | 0 | 1 |
Ciforadenant + Ipilimumab + Nivolumab | Ciforadenant Ipilimumab Nivolumab | 0 | 1 |